Skip to content

What Type Of Collaboration Has Sarepta Therapeutics Entered Into For Duchenne Muscular Dystrophy ?

November 26, 2012

       Sarepta Therapeutics announces in a November 26, 2012 News Release, a collaboration “for the development of an additional exon-skipping drug targeting exon 53, its 4th drug in development, in support ….. treatment of Duchenne Muscular Dystrophy (DMD)”.   

        The collaboration of Sarepta Therapeutics is with : 

–          University College London’s (UCL) scientist, Professor Francesco Muntoni, MD 

–          Institute of Child Health 

–          Dubowitz Neuromuscular Centre. 

         The Orphan Druganaut Blog has been following Sarepta Therapeutics’ orphan drug Eteplirsen, its exon 51-skipping therapeutic candidate for DMD. The company is also developing other exon-skipping drugs for exons 45 and 50.       

Copyright © 2012-2013, Orphan Druganaut Blog.  All rights reserved.

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: